Catalent Global, cGMP Micronizing and Milling for the Pharmaceutical Industry
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products.
With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents.
Catalent has helped innovators ranging from small start-ups to Fortune 5 Pharma companies by optimizing and manufacturing thousands of pharmaceutical, biologic, consumer health and beauty products.
Contact us today to see how we can help you get your product to market faster.
With extensive early phase development expertise in analytics, biologics, pre-formulation and formulation, we can help you achieve faster more efficient development timelines to produce better products.
- In pharmaceuticals we provide expert guidance, pre-screen solubility assessments for drugability, a best-in class API optimization platform, and a wide array of the most up-to-date bioavailability enhancement tools, including particle size reduction, spray drying, hot melt extrusion, and lipid based drug delivery systems.
- In biologics, we help accelerate you to clinic and beyond with GPEx® technology to generate stable, high-performance cell lines.
- In consumer health, we help you deliver innovative products backed by an extensive product library to help get you on the market faster.
Advanced Delivery Technologies
Our innovative dose forms and advanced manufacturing technologies can help you to create better products and therapeutic outcomes to improve the lives of patients and consumers. Our superior enabling formulation technologies can help you meet your target product profile, improve value, and achieve better outcomes, including:
- RP Scherer Softgel Delivery Technologies
- Zydis® Fast Dissolve Delivery Technology
- Advasept® glass-free injectable technology
- SMARTag® antibody drug conjugate technology
Getting product to the market
Whether it’s managing your clinical supply needs or commercially manufacturing your products, we have a solution for you.
- Our clinical supply services can help you manage your local, regional, or global studies, including special handling capabilities and comparator sourcing services.
- Our flexible manufacturing solutions can help you scale up and get to market with tailored solutions and special handling capabilities, all backed by discipline, rigor, and rhythm that has resulted in a reliable global network that will supply your product to the highest quality standards on time.
Products and Services
Clinical Storage, Cold Chain Services and Global Distribution
With a team of packaging experts and extensive cold chain capabilities, Catalent creates custom packaging and distribution solution to meet client's unique needs.
Safinamide is the first new molecule in 20 years to be used in the treatment of Parkinson's.
Early Stage Oral Development
The goal of pre-formulation is to establish the physical, chemical, and mechanical properties of a drug substance that provides a roadmap and a guide for how to formulate the molecule into a fit-for-purpose formulation.
RP Scherer Softgel Technologies
An innovative biotechnology company exploring novel therapeutics for neuroscience indications had developed a promising new chemical entity for the treatment of a severe paediatric genetic disease.
Spray Drying Technology
Around 90% of the drug molecules in the discovery pipeline are insoluble.
AsiaPacific Region Studies, Common Clinical Supply Challenges
The number of clinical trials in the Asia-Pacific (APAC) region is growing as sponsors tap into expanding pharmaceutical market.
Case Study: Assessing Potential for Oral Delivery Using Parallel Screening
Catalent utilised two technologies targeting duodenal and sublingual biological barriers through a parallel screening approach to assess the oral delivery potential of Salmon Calcitonin.
Case Study: Innovative Clinical Supply Solutions
With Catalent's team of packaging experts and extensive cold chain capabilities, this case study discusses the creation of a custom packaging and distribution solution to meet this client’s unique needs.
Case Study: Formulation Prototypes with Increased Solubility and Bioavailability
Catalent Pharma provided London-based pharmaceutical company Trio Medicines with three formulation technologies and four prototypes showing improved solubility and bioavailability for an acetyl prodrug of a novel, well-tolerated G-protein coupled receptor antagonist.
Torrent Pharmaceuticals and Novo Nordisk Insulin and Parenteral Facility
CureVac GMP IV Production Facility, Tubingen
Catalent, a leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies and consumer health products, announced it will present at the 9th Partnership Opportunities in Drug Delivery (PODD) annual conference at the Renaissance Boston Waterfront Hotel, Boston on 7-8 October 2019.Read more
Catalent, a leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies and consumer health products, announced that Alex Haig, Senior Director, Engineering will present at the Pharma Forum at the Bausparkasse Schwäbisch Hall AG, Schwabisch Hall, Germany, on 18-19 September 2019.Read more
Catalent, a leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that Steve Hager, PhD, Senior Director, Technical Support will present at the BioProcess International (BPI) East Conference at the Boston Convention and Exhibition Center, Boston, on 9-12 September.Read more
Catalent, a leading global provider of advanced delivery technologies and development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, has announced that Ben Kester, Manager and Senior Scientist, Purification Development, Catalent Biologics, will present at the upcoming 32nd International Symposium on Preparative and Process Chromatography (PREP Symposium) at the Hyatt Regency Baltimore Inner Harbor, Baltimore, Maryland on 7-10 July 2019.Read more
Catalent Pharma Solutions, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, announces that work to expand its primary packaging capabilities at its clinical facility in Shanghai, China has reached the commissioning stage, with a scheduled completion date of 2018.Read more
Catalent Pharma Solutions has announced it has entered an exclusive agreement with US WorldMeds for the commercial manufacture of lofexidine, an investigational drug under development to mitigate symptoms associated with opioid withdrawal and facilitate completion of opioid discontinuation treatment.Read more
Catalent and Rutgers University Pharmacy Practice Department to Address Paediatric Drug Delivery Challenges
The Catalent Applied Drug Delivery Institute has announced it has entered a collaboration with the Department of Pharmacy Practice at Rutgers University to identify and address the specific challenges of paediatric formulation and drug delivery.Read more
Catalent Pharma Solutions has announced it has broadened the scope of its multi-award winning OptiForm® Solution Suite platform to provide an efficient and seamless path from late-stage discovery to Phase I clinical trials.Read more
Catalent Pharma Solutions has announced it has completed an expansion project at its Kansas City facility to significantly increase controlled-temperature storage capabilities for its clinical supply business.Read more
Catalent Plans to Expand Softgel Development and Manufacturing Capabilities and Capacity Following Accucaps Aqcuisition
Catalent has announced it has completed the acquisition of Accucaps Industries, a Canada-based developer and manufacturer of Over-the-Counter (OTC), high-potency, and conventional pharmaceutical softgels. Financial details of the transaction have not been disclosed.Read more
Catalent Pharma's new state-of-the-art biologics manufacturing facility in Madison utilises single-use systems and offers both flexibility and scale to support your growth.Read more
Catalent To Showcase Aseptic Filling Expertise And Patient-Centric Dose Form Technologies At Pharmapack
Catalent Pharma Solutions (Stand A80) has announced it will be showcasing its specialised expertise and capabilities in aseptic filling and packaging and patient-centric dose form technologies at the upcoming Pharmapack Europe event.Read more
Global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products Catalent has announced that the company has agreed to acquire Accucaps Industries, the Canada-based developer and manufacturer of over-the-counter (OTC), high-potency, and conventional pharmaceutical softgels.Read more
Catalent Biologics Signs a Licence Agreement with Triphase Accelerator Corporation to Advance Smartag ADC to Clinic
Catalent has announced that Triphase Accelerator Corporation will obtain worldwide rights to further develop its proprietary CD22-4AP Antibody-Drug Conjugate (ADC), which has been developed by Catalent's wholly owned subsidiary Redwood Bioscience using its SMARTag™ technology platform.Read more
Catalent has announced it will build a new, flexible GMP space at its Singapore facility with an investment of $4.6M.Read more
Catalent Pharma Solutions has announced that it will invest $4.6m to further expand its Singapore clinical supply facility by building new flexible GMP space for secondary packaging, doubling its ambient storage space, and quadrupling cold storage capacity.Read more
Catalent Biologics and Cerenis Therapeutics Announce Phase III Trial of CER-001 in Europe and North America
Catalent Pharma Solutions has announced that Cerenis Therapeutics has advanced its leading clinical candidate, CER-001, into Phase III clinical studies across Europe and North America.Read more
14 Schoolhouse Road
Somerset, NJ 08873
United States of America
2125 Ambassador Drive
Windsor, N9C 3R5
United States of America
Avenida Jerome Case, 1277,
Sorocaba, SP, 18087-220
399 Chengnan Rd